Zinc Complexes Emerge as Safer Rivals to Platinum Cancer Drugs, Landmark Review Finds

For nearly half a century, the backbone of metal-based cancer chemotherapy has been platinum. Cisplatin and its successors carboplatin and oxaliplatin kill tumor cells by latching onto nuclear DNA and forming rigid cross-links that stall transcription and trigger apoptosis. Yet their clinical value is increasingly undermined by dose-limiting kidney damage, irreversible nerve injury, hearing loss, and the relentless rise of multidrug resistance. Now a sweeping review published in Discover Chemistry by A Arishifa Meeral and Arockiasamy Sebastian of Vellore Institute of Technology in Chennai offers one of the most detailed roadmaps yet for replacing platinum with something far gentler to the human body: zinc.

The appeal of zinc is rooted in basic human biology. It is the second most abundant essential trace element in our physiology, embedded in the catalytic and structural cores of more than 300 metalloenzymes and transcription factors. Unlike open-shell ions such as copper(II) or iron(III), zinc’s closed-shell d10 electronic configuration makes it entirely redox-innocent under physiological conditions. That means it cannot generate destructive hydroxyl radicals through Fenton-type chemistry, sparing healthy tissue from the off-target oxidative degradation that plagues many heavy-metal drugs. Just as importantly, the d10 state carries no ligand field stabilization energy, giving zinc complexes an unusual structural plasticity: the metal readily shifts between coordination numbers four, five, and six, adapting its shape on arrival at intracellular targets.

To harness this flexibility, chemists pair zinc with Schiff base ligands, the so-called privileged scaffolds of coordination chemistry, built by condensing primary amines with carbonyl compounds to create a tunable imine linkage. According to Tweedy’s chelation theory, coordination delocalizes the positive charge of the zinc ion across the entire conjugated chelate ring, reducing the metal’s surface polarity and boosting the complex’s lipophilicity. By adjusting the electronic and steric profiles of peripheral aromatic substituents, researchers can engineer these frameworks to slip passively through the lipid-rich membranes of tumor cells while resisting premature dissociation in the bloodstream.

The new review is not a casual survey. Following a PRISMA-inspired workflow, the authors searched Scopus, Web of Science, and SciFinder for peer-reviewed studies published between 2015 and 2025, retrieving roughly 680 records. After excluding 570 papers that lacked a core imine linkage, definitive crystallographic or spectroscopic geometry, or featured heterometallic centers, and a further 60 that lacked quantitative IC50 cytotoxicity data or docking studies, they distilled the field down to 50 references describing 66 distinct Zn(II) Schiff base complexes, each characterized by techniques ranging from FT-IR and NMR to single-crystal X-ray diffraction.

The comparative analysis reveals that geometry is destiny. Four-coordinate tetrahedral architectures, often built on symmetric N2O2 Salen-type frameworks, excel at dampening charge polarity and optimizing the initial kinetics of cellular uptake. Six-coordinate octahedral complexes, by contrast, offer mechanical advantages inside the cytosol: their geometric distortions create optimized hydrogen-bonding directions and expose planar regions that enable targeted binding to the minor groove of DNA, inducing conformational strain on the double helix and triggering apoptotic cascades in cancer cells while bypassing the efflux pumps responsible for cisplatin resistance. Square-planar designs occupy a middle ground, their flat surfaces ideal for intercalating between DNA base pairs.

The standout performer is a tridentate, octahedral complex labeled 47, built from a pyrazole-pyridyl thiosemicarbazone ligand with acetate and water co-ligands. It achieved an extraordinary IC50 of 0.2013 micromolar against MCF-7 breast cancer cells, the lowest value in the entire dataset. Close behind were a square-planar benzhydrazone complex (IC50 of 4.48 micromolar against MCF-7) that intercalates into nucleic acids, and an ionic complex pairing 1,2-diaminocyclohexane with tolfenamate counterions (IC50 of 5.73 micromolar), whose potency tracks with a strong binding affinity for transfer RNA. In the lung cancer arena, a tetradentate octahedral macrocyclic series showed that tightening computed binding to the VEGFR2 kinase pocket from -7.37 to -8.37 kilocalories per mole translated into a 26.4 percent improvement in cell killing, dropping the IC50 from 8.7 to 6.4 micromolar against A549 cells.

Perhaps the most striking finding is what the authors call the affinity-potency paradox. Several complexes posted jaw-docking computational scores, including one that docked against a DNA dodecamer at -30.56 kilocalories per mole and another that scored an almost unbelievable -301.72 kilocalories per mole against calf thymus DNA, yet proved essentially inactive in living cell assays, with IC50 values above 100 micromolar. The culprit, the review argues, is pharmacokinetics rather than chemistry: neutral, highly symmetric frameworks with enormous crystalline lattice energies are effectively insoluble in water, causing micro-precipitation and sequestration in culture media before the complexes ever reach their targets. Static, cell-free docking scores, the authors caution, are qualitative approximations that must always be validated by experimental cytotoxicity testing.

The review also uncovered a spectroscopic fingerprint that could accelerate future drug design. When the infrared stretching frequency of the azomethine C=N bond was mapped against cytotoxic potency, a clear pattern emerged. The most potent complexes, including the lead compound 47 at 1587 wavenumbers and the tRNA-binding complex 43 at 1599 wavenumbers, all showed markedly red-shifted, lower-energy imine bands, indicating reduced bond order and an electronically adaptive framework capable of flexible target engagement. Conversely, weak or inactive complexes displayed unshifted or blue-shifted bands above 1600 wavenumbers, signatures of rigid, electronically isolated imine units that cannot reorganize to disrupt cell-survival pathways. A simple IR measurement, in other words, may predict which zinc complexes will kill cancer cells before expensive biological screening begins.

Subtle structural changes can also flip biological outcomes entirely. In one striking example, swapping a chlorine substituent for bromine on otherwise identical frameworks reversed the pharmacological profile: the chlorine-bearing complex showed strong antibacterial activity against E. coli with a minimum inhibitory concentration of 64 micrograms per milliliter but weak cytotoxicity against liver cancer cells, while its bromine analogue lost antibacterial potency altogether yet became a highly effective apoptotic agent against HepG2 liver cancer cells. The lesson, the authors note, is that broad generalizations about halogenation effects are invalid; inductive electronic effects must be mapped separately for antimicrobial and oncological pathways.

Significant hurdles remain before any of these compounds reach the clinic. Most primary studies report only raw IC50 values without mapping caspase cascades, mitochondrial depolarization, or cell-cycle arrest, and few include parallel toxicity testing against healthy cell lines, leaving true therapeutic indices unknown. ADME profiles, in vivo efficacy, and systemic bioavailability are almost entirely uncharacterized, and solubility remains a persistent bottleneck, with some complexes dissolving only in organic co-solvents and others refusing to dissolve at all, redirecting them toward photoactive materials instead of medicine. Still, by mapping structure-activity relationships across tetrahedral, square-planar, and octahedral configurations and tying them to spectroscopic and computational benchmarks, the review delivers what inorganic chemists have lacked: a predictable, rational framework for designing non-platinum metallodrugs that pair zinc’s biocompatibility with targeted, geometry-driven cytotoxicity.

Subject of Research: Synthesis, characterization, and anticancer activity of Zn(II) Schiff base coordination complexes

Article Title: A review on the comparative analysis of synthesis, characterization, and biological studies of Zn(II) schiff base complexes

Article References: Meeral, A. A., & Sebastian, A. (2026). A review on the comparative analysis of synthesis, characterization, and biological studies of Zn(II) schiff base complexes. Discover Chemistry, 3(1), Article 567. https://doi.org/10.1007/s44371-026-01005-9

Image Credits: AI Generated

DOI: 10.1007/s44371-026-01005-9

Keywords: zinc complexes, Schiff base, coordination chemistry, anticancer, metallodrugs, cisplatin resistance, molecular docking, structure-activity relationships, infrared spectroscopy, DNA binding, MCF-7, drug design